Name,Category,Begin Date,End Date,Note
Right Upper Quadrant Pain,Milestones,2022-11-01,,Intermittent pain 6 weeks
Ultrasound Abdomen,Biomarker Assess,2022-11-08,,Liver mass identified
MRI with Primovist,Biomarker Assess,2022-11-15,,4.2cm intrahepatic CCA features
CT Chest,Biomarker Assess,2022-11-18,,Lung nodules concerning for mets
Liver Biopsy,Biomarker Assess,2022-11-22,,Intrahepatic cholangiocarcinoma confirmed
Lung Nodule Biopsy,Biomarker Assess,2022-11-28,,Metastatic CCA confirmed
Stage IV Diagnosis,Milestones,2022-12-01,,Liver primary with lung mets
CA 19-9,Biomarker Assess,2022-12-01,,580 U/mL
Molecular Profiling,Biomarker Assess,2022-12-05,,IDH1 R132C mutation detected
GemCis Durvalumab 1L,Line 1 treatment,2022-12-15,2023-05-25,8 cycles first-line
3-Month Restaging,Biomarker Assess,2023-03-15,,Stable disease
6-Month Restaging,Biomarker Assess,2023-06-01,,Slow progression in lung
Progression on 1L,Complications,2023-06-05,,
Ivosidenib Started,Line 2 treatment,2023-06-20,2024-01-15,Tibsovo for IDH1 mutation
8-Week Scan,Biomarker Assess,2023-08-15,,Disease stabilization
CA 19-9 Stable,Biomarker Assess,2023-08-15,,Holding at 290 U/mL
4-Month Scan,Biomarker Assess,2023-10-20,,Continued stable disease
Durable Stability,Biomarker Assess,2024-01-10,,7 months on ivosidenib
FOLFOX 3L Started,Line 3 treatment,2024-01-25,2024-06-15,After ivosidenib progression
